Akebia Therapeutics (AKBA) Enterprise Value (2016 - 2025)
Akebia Therapeutics (AKBA) has disclosed Enterprise Value for 9 consecutive years, with -$184.8 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value fell 256.36% to -$184.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$184.8 million, a 256.36% decrease, with the full-year FY2025 number at -$184.8 million, down 256.36% from a year prior.
- Enterprise Value was -$184.8 million for Q4 2025 at Akebia Therapeutics, down from -$166.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$34.0 million in Q3 2024 to a low of -$247.0 million in Q2 2021.
- A 5-year average of -$106.7 million and a median of -$101.9 million in 2022 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: surged 67.86% in 2023, then crashed 389.14% in 2025.
- Akebia Therapeutics' Enterprise Value stood at -$149.8 million in 2021, then skyrocketed by 39.61% to -$90.5 million in 2022, then skyrocketed by 52.55% to -$42.9 million in 2023, then fell by 20.84% to -$51.9 million in 2024, then crashed by 256.36% to -$184.8 million in 2025.
- Per Business Quant, the three most recent readings for AKBA's Enterprise Value are -$184.8 million (Q4 2025), -$166.4 million (Q3 2025), and -$137.3 million (Q2 2025).